PwC reports that the next segment of the obesity drug market will most likely be characterized by expanded indications, more patient-friendly delivery formats and therapies with stronger adherence profiles
9(1): 1333 Talbot K, Wang HY, Kazi H, et al
Clinical Trials: What Novo Nordisk Knew and When Clinical trials conducted before the FDA approved Ozempic revealed significant evidence of gastrointestinal issues, yet this critical safety information was minimized in Ozempics warning label
The FDA-approved product contains only tirzepatide in its specified concentrations (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection)
[8] [1] The mechanism of delayed gastric emptying is central to semaglutide's therapeutic effects but also accounts for many of its gastrointestinal side effects
Sexual well-being is often overlooked unless patients bring it up